%0 Journal Article %A Tavi Nathanson %A Arun Ahuja %A Alexander Rubinsteyn %A Bulent Arman Aksoy %A Matthew D. Hellmann %A Diana Miao %A Eliezer Van Allen %A Taha Merghoub %A Jedd Wolchok %A Alexandra Snyder %A Jeff Hammerbacher %T Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade %D 2016 %R 10.1101/088286 %J bioRxiv %P 088286 %X Immune checkpoint inhibitors are promising treatments for patients with a variety of malignancies. Toward understanding the determinants of response to immune checkpoint inhibitors, it was previously demonstrated that somatic mutation burden is associated with benefit and a hypothesis was posited that neoantigen homology to pathogens may in part explain the link between somatic mutations and response. To further examine this hypothesis, we reanalyzed cancer exome data obtained from a previously published study of 64 melanoma patients treated with CTLA-4 blockade and a new dataset of RNA-Seq data from 24 of those patients. We found that the predictive accuracy does not increase as analysis narrows from somatic mutation burden to predicted MHC Class I neoantigens, expressed neoantigens, or homology to pathogens. Further, the association between somatic mutation burden and response is only found when examining samples obtained prior to treatment. Neoantigen and expressed neoantigen burden are also associated with response, but neither is more predictive than somatic mutation burden. Neither the previously-described tetrapeptide signature nor an updated method to evaluate neoepitope homology to pathogens were more predictive than mutation burden. %U https://www.biorxiv.org/content/biorxiv/early/2016/11/17/088286.full.pdf